US2012195976A1PendingUtilityA1

Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation

35
Individually held — no corporate assignee on recordPriority: Apr 15, 2002Filed: Dec 9, 2011Published: Aug 2, 2012
Est. expiryApr 15, 2022(expired)· nominal 20-yr term from priority
Inventors:Fritz H. BachPascal O. BerberatSimon Robson
A61P 9/14A61P 41/00A61P 9/10A61P 9/04A61P 7/08A61P 37/06A61P 29/00A61P 25/28A61P 31/12A61P 33/04A61P 33/10A61P 31/04A61P 25/16A61P 33/12A61P 11/06A61P 1/04A61P 13/12A61P 1/16A61P 19/02A61P 17/02A61K 31/455A61K 38/1709A61K 31/19A61K 31/555A61K 38/44A61K 33/00A61K 31/4025A61K 33/26C12Y 114/99003A61K 31/409Y02A50/30
35
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method of transplanting an organ, the method comprising:
 (a) administering to a donor at least one treatment selected from the group consisting of: inducing ferritin in the donor; expressing ferritin in the donor; and administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin to the donor;   (b) obtaining an organ from the donor; and   (c) transplanting the organ into a recipient, wherein the treatment administered in step (a) is sufficient to enhance survival or function of the organ after transplantation into the recipient.   
     
     
         22 . A method of transplanting an organ, the method comprising:
 (a) providing an organ of a donor;   (b) administering to the organ ex vivo at least one treatment selected from the group consisting of: inducing ferritin in the organ; expressing ferritin in the organ; and administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin; and   (c) transplanting the organ into a recipient, wherein treatment administered to the organ in step (b) is sufficient to enhance survival or function of the organ after transplantation of the organ to the recipient.   
     
     
         23 . A method of transplanting an organ, the method comprising:
 (a) providing an organ from a donor;   (b) transplanting the organ into a recipient; and   (c) before, during, or after step (b), administering to the recipient at least one treatment selected from the group consisting of: inducing ferritin in the recipient; expressing ferritin in the recipient; and administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinyl hydrazone, iron dextran, or apoferritin to the recipient, wherein the treatment administered to the recipient in step (c) is sufficient to enhance survival or function of the organ after transplantation of the organ to the recipient.   
     
     
         24 . The method of  claim 21 , further comprising the step of administering to the donor at least one treatment selected from the group consisting of: inducing HO-1 in the donor; expressing HO-1 in the donor; and administering a pharmaceutical composition comprising carbon monoxide to the donor. 
     
     
         25 . The method of  claim 21 , further comprising the steps of inducing HO-1 in the donor, and administering a pharmaceutical composition comprising carbon monoxide to the donor. 
     
     
         26 . The method of  claim 22 , further comprising the step of administering to the patient at least one treatment selected from the group consisting of: inducing HO-1 in the organ; expressing HO-1 in the organ; and administering a pharmaceutical composition comprising carbon monoxide to the organ. 
     
     
         27 . The method of  claim 22 , further comprising the steps of inducing HO-1 in the organ and administering a pharmaceutical composition comprising carbon monoxide to the organ. 
     
     
         28 . The method of  claim 23 , further comprising the step of administering to the patient at least one treatment selected from the group consisting of: inducing HO-1 in the recipient; expressing HO-1 in the recipient; and administering a pharmaceutical composition comprising carbon monoxide to the recipient. 
     
     
         29 . The method of  claim 23 , further comprising the steps of inducing HO-1 in the recipient, and administering a pharmaceutical composition comprising carbon monoxide to the recipient. 
     
     
         30 - 41 . (canceled) 
     
     
         42 . The method of  claim 21 , wherein the pharmaceutical composition is administered and the composition comprises ferritin. 
     
     
         43 . The method of  claim 21 , wherein the pharmaceutical composition is administered and the composition comprises biliverdin. 
     
     
         45 . The method of  claim 21 , wherein the pharmaceutical composition is administered and the composition comprises bilirubin. 
     
     
         46 . The method of  claim 21 , wherein the pharmaceutical composition is administered and the composition comprises iron dextran. 
     
     
         47 . The method of  claim 21 , wherein the pharmaceutical composition is administered and the composition comprises apoferritin. 
     
     
         49 . The method of  claim 22 , wherein the pharmaceutical composition is administered and the composition comprises ferritin. 
     
     
         50 . The method of  claim 22 , wherein the pharmaceutical composition is administered and the composition comprises biliverdin. 
     
     
         52 . The method of  claim 22 , wherein the pharmaceutical composition is administered and the composition comprises bilirubin. 
     
     
         53 . The method of  claim 22 , wherein the pharmaceutical composition is administered and the composition comprises iron dextran. 
     
     
         54 . The method of  claim 22 , wherein the pharmaceutical composition is administered and the composition comprises apoferritin. 
     
     
         56 . The method of  claim 23 , wherein the pharmaceutical composition is administered and the composition comprises ferritin. 
     
     
         57 . The method of  claim 23 , wherein the pharmaceutical composition is administered and the composition comprises biliverdin. 
     
     
         59 . The method of  claim 23 , wherein the pharmaceutical composition is administered and the composition comprises bilirubin. 
     
     
         60 . The method of  claim 23 , wherein the pharmaceutical composition is administered and the composition comprises iron dextran. 
     
     
         61 . The method of  claim 23 , wherein the pharmaceutical composition is administered and the composition comprises apoferritin. 
     
     
         62 . The method of  claim 23 , wherein the pharmaceutical composition is administered and the composition comprises iron.

Join the waitlist — get patent alerts

Track US2012195976A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.